Evogene Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Evogene Ltd. - overview
Established
2002
Location
Rehovot, -, Israel
Primary Industry
Biotechnology
About
Evogene Ltd. is a biotechnology firm specializing in life-science products, leveraging its Computational Predictive Biology Platform to develop innovative solutions for human health, agriculture, and industrial applications. Founded in 2002, Evogene Ltd. is headquartered in Rehovot, Israel.
The company operates primarily in the biotechnology sector, focusing on developing life-science products through advanced computational biology. Evogene has secured a total of USD 73. 75 mn in funding, with its latest round being a Private Placement/Follow on, amounting to USD 73. 75 mn.
To date, the company has completed 4 deals. Evogene Ltd. specializes in the development of innovative life-science products through its proprietary Computational Predictive Biology (CPB) Platform, which integrates advanced artificial intelligence technologies with extensive scientific research and big data analysis. This platform is designed to enhance the discovery and development of products in three primary categories: microbe-based products, small molecule-based products, and genetic element-based products.
Each product line addresses specific challenges in various sectors, including human health, agriculture, and industrial applications. The company's solutions are tailored for a diverse clientele, which includes pharmaceutical companies, agricultural innovators, and industrial firms, primarily serving markets in North America, Europe, and Asia. In 2022, Evogene reported a revenue of USD 1. 68 mn, alongside an EBITDA loss of USD 24.
36 mn. The company generates revenue through licensing agreements and strategic partnerships leveraging its advanced technology solutions. Evogene engages in B2B transactions, providing clients access to its CPB Platform and associated tech engines, such as MicroBoost AI, ChemPass AI, and GeneRator AI, typically through multi-year contracts. Evogene plans to leverage its recent funding from Binder and Partners Family Office to further develop its portfolio of products and advance its market reach.
The company is focusing on launching new products designed to address specific market needs and is exploring expansion into new geographic regions, although specific markets and timelines have not been disclosed. The funding will support these initiatives, allowing Evogene to enhance its technological offerings and strengthen partnerships within defined commercial fields.
Current Investors
Binder and Partners Family Office, GlenRock Israel
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Agricultural Chemicals
Website
www.evogene.com
Verticals
Agtech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Evogene Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Placement/Follow on | Completed | Evogene Ltd. | - | ||||||||
| IPO | Completed | Evogene Ltd. | - | ||||||||
| Buyout | Completed | Evogene Ltd. | - | ||||||||
| PIPE | Completed | Evogene Ltd. | - |
Displaying 1 - 4 of 4
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.